ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023
2023年5月4日 - 9:00PM
ビジネスワイヤ(英語)
ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that
the company will report financial results for the three months
ended March 31, 2023 on Monday, May 15, 2023 after the close of
trading on the U.S. financial markets. Management will host a
conference call and webcast beginning at 4:30 p.m. Eastern time to
discuss the results, provide an update on recent corporate
developments and answer questions.
Participants are encouraged to pre-register for the conference
call using this link. Callers who pre-register will receive a
unique PIN to gain immediate access to the call and bypass the live
operator. Participants may register at any time, including up to
and after the call start time. Those unable to pre-register may
participate by dialing (844) 868-8846 (U.S.) or (412) 317-5465
(International). A webcast of the call can also be accessed at
ENDRA’s Investor Relations page and here.
A telephone replay will be available until May 22, 2023 by
dialing (877) 344-7529 (U.S.) or (412) 317-0088 (International) and
providing the passcode 8983905. A webcast replay will be available
beginning approximately one hour after the completion of the live
conference call here.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
the more than 700,000 ultrasound systems in use globally today.
TAEUS® is initially focused on the measurement of fat in the liver
as a means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver
conditions that affect over two billion people globally, and for
which there are no practical diagnostic tools. Beyond the liver,
ENDRA is exploring several other clinical applications of TAEUS®,
including visualization of tissue temperature during energy-based
surgical procedures. For more information, please visit
www.endrainc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230504005141/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com Investor
Relations Contact: Yvonne Briggs LHA Investor Relations (310)
691-7100 ybriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
過去 株価チャート
から 4 2024 まで 5 2024
ENDRA Life Sciences (NASDAQ:NDRA)
過去 株価チャート
から 5 2023 まで 5 2024